Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Fluoxetine in the treatment of obese type 2 diabetic patients.

O'Kane M, Wiles PG, Wales JK.

Diabet Med. 1994 Jan-Feb;11(1):105-10.

PMID:
8181239
2.

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J.

Diabetes Care. 1998 Aug;21(8):1288-94.

PMID:
9702435
3.

Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.

Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, Jadzinsky M, Barranco J, Aschner P, Ramirez L, Matos AG.

Diabetes Obes Metab. 2003 May;5(3):180-8.

PMID:
12681025
4.
5.

A study of fluoxetine in obese elderly patients with type 2 diabetes.

Connolly VM, Gallagher A, Kesson CM.

Diabet Med. 1995 May;12(5):416-8.

PMID:
7648804
6.

Pharmacologic induction of weight loss to treat type 2 diabetes.

Redmon JB, Raatz SK, Kwong CA, Swanson JE, Thomas W, Bantle JP.

Diabetes Care. 1999 Jun;22(6):896-903.

7.

Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients.

Hermann LS, Kalén J, Katzman P, Lager I, Nilsson A, Norrhamn O, Sartor G, Ugander L.

Diabetes Obes Metab. 2001 Dec;3(6):428-34.

PMID:
11903415
8.

Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study.

Daubresse JC, Kolanowski J, Krzentowski G, Kutnowski M, Scheen A, Van Gaal L.

Obes Res. 1996 Jul;4(4):391-6.

9.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
10.

No relationship between carbohydrate intake and effect of acarbose on HbA1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30-60% of energy from carbohydrate.

Wolever TM, Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH.

Diabetes Care. 1998 Oct;21(10):1612-8.

PMID:
9773719
11.

Dexfenfluramine in type II diabetes: effect on weight and diabetes control.

Stewart GO, Stein GR, Davis TM, Findlater P.

Med J Aust. 1993 Feb 1;158(3):167-9.

PMID:
8450782
12.

Intensive insulin therapy combined with metformin in obese type 2 diabetic patients.

Fritsche A, Schmülling RM, Häring HU, Stumvoll M.

Acta Diabetol. 2000 Mar;37(1):13-8.

PMID:
10928231
13.

Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.

Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M, Foreyt J, Aronne L, Klein S.

Diabetes Care. 2002 Jul;25(7):1123-8. Erratum in: Diabetes Care. 2002 Sep;25(9):1671..

PMID:
12087008
14.
16.

Bromocriptine: a novel approach to the treatment of type 2 diabetes.

Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, Pipek R, Iozzo P, Lancaster JL, Cincotta AH, DeFronzo RA.

Diabetes Care. 2000 Aug;23(8):1154-61.

18.

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus.

Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, Weinstein SP; Sibutramine/Diabetes Clinical Study Group.

Diabetes Obes Metab. 2000 Jun;2(3):175-87.

PMID:
11220553
19.

Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes.

Boden G, Sargrad K, Homko C, Mozzoli M, Stein TP.

Ann Intern Med. 2005 Mar 15;142(6):403-11.

PMID:
15767618
20.

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS.

Diabetes Care. 1998 May;21(5):701-5.

PMID:
9589227
Items per page

Supplemental Content

Write to the Help Desk